Biohaven Ltd. (NYSE:BHVN) Stake Raised by Bison Wealth LLC

Bison Wealth LLC grew its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 332,428 shares of the company’s stock after buying an additional 1,440 shares during the period. Biohaven accounts for 2.7% of Bison Wealth LLC’s investment portfolio, making the stock its 6th biggest position. Bison Wealth LLC owned approximately 0.33% of Biohaven worth $12,416,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company’s stock valued at $314,267,000 after buying an additional 628,211 shares during the period. Stifel Financial Corp lifted its stake in shares of Biohaven by 0.8% in the 4th quarter. Stifel Financial Corp now owns 6,559,313 shares of the company’s stock valued at $244,990,000 after purchasing an additional 50,052 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company’s stock worth $73,922,000 after purchasing an additional 1,169,721 shares during the period. Geode Capital Management LLC increased its position in Biohaven by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company’s stock worth $71,182,000 after purchasing an additional 190,754 shares in the last quarter. Finally, ARS Investment Partners LLC raised its holdings in Biohaven by 1.0% in the fourth quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company’s stock valued at $38,871,000 after buying an additional 10,473 shares during the period. 88.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BHVN. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Thursday, April 24th. Robert W. Baird lowered their target price on Biohaven from $60.00 to $57.00 and set an “outperform” rating for the company in a research note on Monday. Deutsche Bank Aktiengesellschaft set a $60.00 price target on Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. Morgan Stanley dropped their price target on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating on the stock in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $54.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $62.54.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs purchased 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 16.00% of the stock is owned by corporate insiders.

Biohaven Stock Up 0.7 %

BHVN stock opened at $21.89 on Wednesday. The stock has a market cap of $2.23 billion, a PE ratio of -2.34 and a beta of 1.33. The firm’s 50-day simple moving average is $25.73 and its 200 day simple moving average is $37.08. Biohaven Ltd. has a fifty-two week low of $15.79 and a fifty-two week high of $55.70.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Equities analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.